• About us
  • People
  • Expertise
    • Sectors
        • Technology, media & communications Technology, media & communications
        • Private Wealth Private wealth
        • Real estate, infrastructure & energy
        • Life sciences & healthcare icon Life sciences & healthcare
        • Aerospace & defence
        • Automotive & mobility
        • Business & professional services
        • Chemicals
        • Consumer & retail
        • Financial institutions & insurance
        • Hotels, hospitality & leisure
        • Logistics & transport
        • Manufacturing & industrials
        • Public services & education
    • Legal services
        • Artificial intelligence
        • Banking & finance
        • Brands & advertising
        • Commercial & consumer contracts
        • Competition, EU & trade
        • Copyright & media law
        • Corporate crime & compliance
        • Corporate/M&A & capital markets
        • Data & cyber
        • Disputes & investigations
        • Employment, pensions & mobility
        • Environmental, planning & regulatory
        • Environmental, social & governance (ESG)
        • Intellectual property
        • Information technology
        • Patents & innovation
        • Private client
        • Private equity
        • Projects, energy & infrastructure
        • Real estate & construction
        • Regulation
        • Restructuring & insolvency
        • Tax
        • Venture capital
  • Locations
    • Europe
        • Locations
        • Austria
        • Belgium
        • Czech Republic
        • France
        • Germany
        • Hungary
        • Italy
        • Netherlands
        • Poland
        • Portugal
        • Ireland
        • Slovakia
        • Spain
        • United Kingdom
        • Ukraine
          Groups & regions
        • CEE Turkish Desk
        • French German group
        • Our offices
    • Middle East & Africa
        • Locations
        • Middle East
        • UAE
          Groups
        • Africa group
        • Israel group
        • Our offices
    • Americas
        • Locations
        • Latin America
        • USA
          Groups
        • Brazil group
        • Our offices
    • Asia
        • Locations
        • Asia
        • China
        • South Korea
          Groups
        • India group
        • Japan group
        • Our offices
  • Insights
    • Insights
        • Featured Topics
        • Artificial intelligence
        • Data Centre Expertise
        • The EU Whistleblower Directive
        • German Supply Chain Act
        • Unified Patent Court
          Content hub
        • Global Data Hub
        • Interface: tech, IP and media law
        • Podcasts
        • Synapse
        • Browse all insights
    • In focus
        • AI
        • Dealonomics
        • Disputes
        • Intellectual property
        • MENA
        • Regulation
        • Browse in focus
    • Events
        • In person
        • Online
        • Browse all events
    • News
        • Media centre
        • Work highlights
        • Firm news
        • Browse all news
  • Careers
  • EN
    • English
    • 中文(简体)
    • Français
    • Deutsch
  • Home
  • People
  • Ross McNaughton
Ross McNaughton
Ross McNaughton

Ross McNaughton

Partner

  • Cambridge UK
Contact Me Today
+44 1223 446 443
vCard
Email me Call me
Featured award

Legal 500 UK 2026

Leading partner in the venture capital, biotechnology and corporate and commercial: Cambridge categories.

Scroll to featured award

Ross is a partner in the Corporate and Life Sciences team, based in our Cambridge office.

Ross is a lead partner within the firm's Tier 1-ranked Biotechnology practice in Cambridge. His practice involves helping life sciences and technology companies as they progress through their life cycle in all aspects of their growth, capital raising and international expansion. As a sector specialist, Ross focuses on biotech, medical devices and diagnostics within Life Sciences, and with the Tech sector supports companies operating in the capital intensive deep tech space, including quantum computing, artificial intelligence, advanced materials, as well as web3.

Ross has extensive experience of a variety of venture and growth financing, public capital raisings, mergers and acquisitions and general corporate advice. Ross was based out of San Francisco, CA in 2018 – 19 and as a result, he has a particular expertise in transactions with a transatlantic component.

Expertise

Services and Groups

Corporate/M&A & capital markets
Venture capital
Artificial intelligence
M&A

Sectors

Life sciences & healthcare
Technology, media & communications
Cryptoassets, blockchain and distributed ledger technology
Machine learning

CV

Since 2020 Partner, Taylor Wessing LLP
2015 - 2020 Partner, Penningtons Manches Cooper LLP, Cambridge
2010 - 2015 Partner, Paul Hastings LLP, London
2002 - 2009 Lawyer, Herbert Smith
2018 Admitted as a foreign legal consultant, state bar of California
2004 Admitted as a lawyer, England and Wales
2001 LPC and Post Graduate Degree in Law, Nottingham Law School

Career

Since 2020 Partner, Taylor Wessing LLP
2015 - 2020 Partner, Penningtons Manches Cooper LLP, Cambridge
2010 - 2015 Partner, Paul Hastings LLP, London
2002 - 2009 Lawyer, Herbert Smith

Education

2018 Admitted as a foreign legal consultant, state bar of California
2004 Admitted as a lawyer, England and Wales
2001 LPC and Post Graduate Degree in Law, Nottingham Law School

Additional languages

English

Awards

Legal 500 UK 2026

Featured

Leading partner in the venture capital, biotechnology and corporate and commercial: Cambridge categories.

Legal 500 UK 2025

Leading partner

Legal 500 UK 2025

Leading partner

Legal 500 UK 2025

Leading partner

Corporate/M&A (mid-market and private equity) - Band 3: Ross McNaughton heads up the Cambridge corporate department at Taylor Wessing and represents a variety of technology and pharmaceutical clients in complex acquisitions. He also has strong expertise in financing matters. "Ross McNaughton has strong knowledge and sector experience."

‘A strength of Taylor Wessing is the depth of knowledge and expertise across different legal areas, and we were able to access this on a particularly complex transaction under the truly excellent leadership of Ross McNaughton.’ ‘Ross McNaughton and Adrian Toutoungi are our go-to partner specialists.’

Venture capital

Corporate and commercial - Cambridge (Leading individual): "Ross McNaughton was a key negotiating ally in our dealings with both investors and potential acquirers. He was able to lead complex and difficult interactions with third parties in a pragmatic and ultimately successful manner." "Ross McNaughton performed superbly during deal negotiations. His tenacity and ability to direct a legal team is commendable."

Biotechnology

Recognised as a notable practitioner

Venture capital

Experience

Advising on Draig Therapeutics' US$140 million series A financing

We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.

Press release
Ross McNaughton
Elinor Picton
Oli Denne
Helen Farr
Adrian Toutoungi
Charlie Adams
Nicholas Vollers
Ed Chapman

Blue Earth Therapeutics on the closing of US$76.5 million Series A funding

We have advised Blue Earth Therapeutics and its management on the closing of US$76.5 million Series A funding. The new funding comes from a broad spectrum of experienced biotech investors and enables Blue Earth Therapeutics to further advance its clinical stage prostate-specific membrane antigen-targeted radioligand therapies.

Press release
Ross McNaughton
Bella Thornton-Clark

Healx raises $47 million in its Series C funding

Advised Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases based in Cambridge UK, on its $47 million Series C funding. The funding was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s largest venture capital firms, with participation from new and existing investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners.

Press release
Ross McNaughton
Oli Denne

Advising gene therapy company AlveoGene on its complex spinout and launch investment

We have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.

Press release
Ross McNaughton
Bella Thornton-Clark

Advising on transformational life sciences combinations and cross-over rounds

Ross was the lead partner on the transformational roll-up and $250 million cross-over financing of Centessa Pharmaceuticals, representing eight cutting-edge UK and European biotech companies on their participation in a newly established holding company focused on the development of innovative new treatments. Ross was also the lead partner on the combination of three New Science Ventures-backed companies under Ventyx Biosciences Inc in the context of its concurrent $114 million financing led by venBio Partners.

Ross McNaughton

Acting on venture growth rounds for leading life sciences and tech businesses

Ross constantly acts for leading growth companies and investors on their funding rounds, including recently Cambridge Epigenetix on its $88 million series D funding round led by Temasek, Envelop Risk on its $130 million round led by SoftBank, and Oxbotica on its $47 million series B investment.

Ross McNaughton

Ross's news & insights

View Ross's insights
Up Arrow
Click here to find out more
Corporate/M&A & capital markets

Advising Lingotto on its extended Series A funding into Optalysys to US$60 million

6 February 2026

by multiple authors

Glass.Mapper.Sc.Fields.Image?.Alt
Corporate/M&A & capital markets

Advising on Infinitopes' expanded seed financing to US$35 million

3 February 2026

by Ross McNaughton and Oli Denne

Click here to find out more
Glass.Mapper.Sc.Fields.Image?.Alt
Life sciences & healthcare

Advising Nuclera on its extended Series C funding to US$87 million

22 January 2026

by Ross McNaughton and Oli Denne

Click here to find out more
View Ross's insights

Related news & insights

Escalator
Consumer & retail

Consumer and Retail in the News

20 February 2026
Quick read

by multiple authors

Click here to find out more
Androids and facial mapping
Technology, media & communications

What international businesses should know about the German AI Market Surveillance and Innovation Promotion Act

20 February 2026
Briefing

by multiple authors

Click here to find out more
Robots hand
Technology, media & communications

The “Withdrawal Button”: A new compliance risk for (non-)EU businesses

20 February 2026
Briefing

by Nathalie Koch, LL.M. (UC Hastings) and Elisa-Marlen Dietrich, LL.M. (Turin)

Click here to find out more
Patterned pills
Life sciences & healthcare

Reform of the MDR and IVDR – A critical look at the Commission's proposal of 16 December 2025

19 February 2026
In-depth analysis

by Dr. Wolfgang Rehmann

Click here to find out more
Search Result Thumbnail Crypto
Corporate/M&A & capital markets

Clearer rules on cryptocurrency trading

19 February 2026
Briefing

by Ákos Mátés-Lányi, LL.M., MRICS

Click here to find out more
Full Frame Shot Of Orange Cable
Projects, energy & infrastructure

The NIS2 Directive: Challenges Renewable Energy Companies

18 February 2026
Briefing

by Dr. Paul Voigt, Lic. en Derecho, CIPP/E

Click here to find out more
Up Arrow
Corporate/M&A & capital markets

Advising Shorooq on its investment in Safqah Capital

18 February 2026

by multiple authors

Click here to find out more
Fintech

Agentic AI in payments: Key regulatory considerations

17 February 2026
In-depth analysis

by Miroslav Đurić, LL.M.

Click here to find out more
Environmental, social & governance (ESG)

Modifications to the CSRD under the EU’s Omnibus Package

16 February 2026
In-depth analysis

by Dr. Rebekka Krause

Click here to find out more
Financial services regulatory

Stablecoins: no longer the new kid on the block

16 February 2026
Briefing

by multiple authors

Click here to find out more
View all insights

Related people

UK
Global
James Homan

James Homan

Partner

London
+44 20 7300 4124
Email me
View profile

Jack Coventry

Senior Associate

London
+44 20 7300 7000
Email me
View profile
Nell Cooper

Nell Cooper

Senior Associate

London
+44 20 7300 7000
Email me
View profile
Dillan Madhani

Dillan Madhani

Associate

London
+44 20 7300 7000
Email me
View profile

Mike Vallance

Associate

London
+44 20 7300 7000
Email me
View profile
Katie Chandler

Katie Chandler

Partner

London
+44 20 7300 4163
Email me
View profile
Timothy Pinto

Timothy Pinto

Senior Counsel

London
+44 20 7300 7000
Email me
View profile

Edward Waldron

Partner

London
+44 (0)20 7300 4968
Email me
View profile

Clover May

Associate

London
+44 20 7300 7000
Email me
View profile
Ian Moore

Ian Moore

Partner

London
+44 20 7300 4664
Email me
View profile
Full team
Holger Schrewe

Dr. Holger Schrewe, LL.M. (London)

Partner

Hamburg
+49 40 36803 0
Email me
View profile
Dániel Ódor

Dániel Ódor, MRICS

Partner

Budapest
+36 1 32 70 407
Email me
View profile
Detlef Klett

Detlef Klett

Partner

Duesseldorf
+49 211 8387 0
Email me
View profile
Emma Danks

Emma Danks

Partner

London
+44 20 7300 4718
Email me
View profile

Dr. Gunbritt Kammerer-Galahn

Partner

Duesseldorf
+49 211 8387 0
Email me
View profile
Tessa Giltay

Tessa Giltay

Senior Associate

Amsterdam
+31 88 02 43 192
Email me
View profile
David Klein

Dr. David Klein, LL.M. (Univ. of Washington), CIPP/E

Salary Partner

Hamburg
+49 40 36803 0
Email me
View profile
Abdullah Mutawi

Abdullah Mutawi

Partner

Dubai
London
+971 43 09 1031
Email me
View profile
Benjamin Znaty

Benjamin Znaty

Counsel

Paris
+33 172 74 03 33
Email me
View profile
Olav Nemling

Olav Nemling

Partner

Warsaw
+48 22 5849740
Email me
View profile
Full team

Meet me at

There are no upcoming events

See all events
Subscribe to our latest insights
  • About us
  • Campaigns and online tools
  • News
  • People
  • Expertise
  • Locations
  • Insights
  • Events
  • Media centre
  • Contact
  • Careers
  • Alumni
  • Data protection & privacy policy
  • Cookie policy
  • Legal and regulatory information
  • Regulatory information on costs
  • Complaints procedure for clients
  • Terms of use
  • Anti-slavery statement
  • Environmental
  • Scam emails

© Taylor Wessing